ANDREW LEE was named medical director of the Texas Center for Proton Therapy, a collaboration of Texas Oncology, Baylor Health, McKesson Specialty Health, and The US Oncology Network, effective Feb. 1.
PELOTONIA awarded six, two-year grants to projects at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital & Richard J. Solove Research Institute.
MOUNT SINAI HEALTH SYSTEM and Valley Health System announced plans to collaborate on clinical programs, research and educational initiatives. Mount Sinai comprises seven hospitals and the Icahn School of Medicine at Mount Sinai. Valley Health System, headquartered in Ridgewood, N.J., includes The Valley Hospital, Valley Home Care and Valley Medical Group.
THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY and the College of American Pathologists announced a partnership to further inter-professional education, advocacy, quality improvement, international outreach, and practice guideline development. The two organizations signed a memorandum of understanding.
THE BARBARA ANN KARMANOS CANCER INSTITUTE received a grant of $5,375,000 from the Dresner Foundation. The grant, focused on hematologic malignancies research, will be distributed over the next five years.
ROCHE acquired Bina Technologies Inc., a privately held company that provides a big data platform for centralized management and processing of next generation sequencing data for the academic and translational research markets.
SETON HALL UNIVERSITY and Hackensack University Health Network announced plans to form a new, four-year school of medicine. The partnership will establish the only private school of medicine in New Jersey.
NAIYER RIZVI was named director of thoracic oncology and immunotherapeutics in medical oncology at NewYork-Presbyterian/Columbia University Medical Center. Rizvi comes from Memorial Sloan Kettering Cancer Center, where he was an attending physician and focused on thoracic immunotherapy.
JULIE BRAHMER was named director of the Thoracic Oncology Program at the Johns Hopkins Kimmel Cancer Center.
MD Anderson, Intrexon, and Ziopharm announce sublicensing agreement with the University of Minnesota
MD ANDERSON CANCER CENTER, Intrexon Corporation and Ziopharm Oncology announced a sublicensing agreement for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies.
